HDAC3 Antibody

What is HDAC3 and why is it a significant target for antibody-based research?

HDAC3 (Histone Deacetylase 3) is a critical member of the class I mammalian histone deacetylases involved in regulating chromatin structure during transcription. It catalyzes the removal of acetyl groups from lysine residues of histones and other cellular proteins . HDAC3 forms multi-protein complexes with the co-repressors SMRT and N-CoR to regulate the transcription of numerous genes, extending its role beyond simple transcriptional repression . As a ubiquitously expressed enzyme capable of deacetylating both H3 and H4 in free histones or nucleosome substrates, HDAC3 represents an important target for understanding epigenetic regulation mechanisms in various biological contexts.

The significance of studying HDAC3 has been underscored by its involvement in:

• Tumor microenvironment regulation

• Antitumor immune responses

• Inflammatory gene network control

• Neurological recovery after injury

• Transcriptional silencing in various cancer types

How do I determine which HDAC3 antibody application is most suitable for my research question?

Selecting the appropriate application depends on your specific research question:

For each application, perform pilot experiments to determine optimal conditions for your specific cell line or tissue. HDAC3 antibodies have been validated in multiple cell lines including A431, HeLa, HepG2, Jurkat, and K-562 cells .

What are the expected molecular weight and banding patterns for HDAC3 in Western blot analysis?

When performing Western blot analysis for HDAC3:

• The calculated molecular weight of HDAC3 is 49 kDa

• The observed molecular weight in most experimental systems is also 49 kDa

• Use positive control lysates from validated cell lines such as A431, HL-60, HeLa, U-251, HEK-293, HepG2, Jurkat, or K-562 cells

If additional bands appear, consider:

• Post-translational modifications of HDAC3

• Splice variants

• Degradation products

• Non-specific binding

Always include appropriate positive and negative controls, especially HDAC3 knockout/knockdown samples when available, to confirm antibody specificity.

How can I optimize HDAC3 ChIP experiments to study its binding to specific gene promoters?

Optimizing HDAC3 ChIP experiments requires careful consideration of several factors:

• Antibody selection: Use ChIP-validated antibodies such as the HDAC3 monoclonal antibody (C15200145) that has been specifically validated for ChIP-qPCR applications .

• Crosslinking conditions: For HDAC3, standard 1% formaldehyde for 10 minutes at room temperature works well, but optimization may be required for different cell types.

• Sonication parameters: Aim for chromatin fragments between 200-500 bp.

• Target genes: Based on research findings, HDAC3 directly binds to promoter regions of chemokine genes CXCL9, CXCL10, and CXCL11 to inhibit their expression . These represent excellent positive control targets.

• Controls: Include:

  • Input control (pre-immunoprecipitated chromatin)

  • IgG control (same isotype as HDAC3 antibody)

  • Positive control (known HDAC3 binding region)

  • Negative control (region without HDAC3 binding)

When analyzing data, compare enrichment to input and normalize to IgG controls. For studying HDAC3's role in regulating inflammatory genes, focus on promoter regions of CXCL9/10/11 chemokines, as HDAC3 has been shown to directly bind to these regions and regulate their expression in tumor microenvironments .

What strategies can I employ to study HDAC3 interaction with co-repressor complexes?

To study HDAC3 interactions with co-repressor complexes such as SMRT and N-CoR:

• Co-immunoprecipitation (Co-IP):

  • Use 0.5-4.0 μg of HDAC3 antibody for 1.0-3.0 mg of total protein lysate

  • Include appropriate controls (IgG, input, reverse Co-IP)

  • Consider mild lysis conditions to preserve protein-protein interactions

  • Western blot for known HDAC3 interaction partners (SMRT, N-CoR)

• Proximity Ligation Assay (PLA):

  • Provides visual confirmation of protein-protein interactions

  • Requires antibodies from different species for HDAC3 and interacting partners

  • Allows quantification of interaction events

• Sequential ChIP (ChIP-reChIP):

  • Perform first ChIP with HDAC3 antibody

  • Elute complexes and perform second ChIP with antibody against potential partner

  • Identify genomic regions bound by both proteins

• Mass Spectrometry following IP:

  • Immunoprecipitate HDAC3 complexes

  • Analyze by mass spectrometry to identify novel interaction partners

  • Validate findings with targeted Co-IP experiments

These techniques can help elucidate how HDAC3 forms functional complexes that regulate gene expression, particularly in contexts like BCL6/SMRT/HDAC3 complexes that mediate aberrant transcriptional silencing in B-cell lymphomas .

How can I effectively investigate the relationship between HDAC3 activity and chemokine expression in tumor microenvironments?

Based on recent research showing HDAC3's role in regulating chemokine expression and immune cell recruitment in the tumor microenvironment (TME), consider these approaches:

• HDAC3 knockdown/knockout studies:

  • Generate HDAC3 KO tumor cell lines using CRISPR-Cas9

  • Compare chemokine expression (CXCL9/10/11) between wild-type and HDAC3-deficient cells

  • Assess tumor growth in immunocompetent vs. immunodeficient mice

  • Analyze immune cell infiltration in the TME

Research findings demonstrate that HDAC3-deficient tumor cells express higher levels of CXCL9, CXCL10, and CXCL11 chemokines, which suppress tumor growth by recruiting CXCR3+ T cells into the TME .

• ChIP-Seq analysis:

  • Perform HDAC3 ChIP-Seq in tumor cells

  • Analyze binding patterns at chemokine gene promoters

  • Correlate with histone acetylation status (H3K9ac)

  • Integrate with RNA-Seq data to correlate binding with expression changes

• HDAC3 inhibitor studies:

  • Treat tumor cells with selective HDAC3 inhibitors

  • Measure changes in chemokine expression

  • Assess effects on immune cell recruitment and tumor growth

  • Compare results in different tumor models

• Tissue analysis:

  • Use HDAC3 antibodies (1:20-1:200 dilution) for IHC in tumor tissues

  • Evaluate correlation between HDAC3 expression and CXCL10 levels

  • Quantify CD8+ T-cell infiltration

  • Analyze patient survival outcomes

Research has revealed an inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma tissues, suggesting HDAC3's involvement in antitumor immune regulation and patient survival .

What are common challenges when using HDAC3 antibodies in Western blot, and how can they be resolved?

For optimal results:

• Use freshly prepared lysates

• Include appropriate positive controls

• Consider the buffer composition (70 mM Tris pH 8, 105 mM NaCl, 31 mM glycine, 0.07 mM EDTA, 30% glycerol)

• Validate results with alternative HDAC3 antibody clones (e.g., clone 3G6 or polyclonal antibodies)

How can I improve specificity and reduce background in HDAC3 immunohistochemistry?

For optimal HDAC3 immunohistochemistry results:

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval (pressure cooker or microwave)

• Antibody dilution:

  • Start with recommended 1:20-1:200 dilution

  • Titrate for your specific tissue type

  • Incubate overnight at 4°C for improved specificity

• Blocking optimization:

  • Use 5-10% normal serum from the species of secondary antibody

  • Consider dual blocking with serum and BSA

  • Add 0.1-0.3% Triton X-100 for better penetration

• Controls:

  • Negative control: Omit primary antibody

  • Positive control: Tissues known to express HDAC3 (e.g., human ovary tumor tissue)

  • Peptide competition: Pre-incubate antibody with immunizing peptide

  • HDAC3 knockout/knockdown tissues when available

• Signal amplification:

  • Consider polymer-based detection systems

  • Tyramide signal amplification for low abundance targets

  • Balance sensitivity with background

HDAC3 shows both nuclear and cytoplasmic localization patterns depending on cell type and context. Validate subcellular localization patterns with immunofluorescence studies in well-characterized cell lines.

What controls should be included when validating HDAC3 antibody specificity?

Comprehensive validation of HDAC3 antibody specificity requires multiple controls:

• Genetic controls:

  • HDAC3 knockout cells/tissues (gold standard)

  • HDAC3 knockdown samples (siRNA or shRNA)

  • Comparison of signals between these samples and wild-type

• Expression controls:

  • Overexpression systems (recombinant HDAC3)

  • Cells known to express high vs. low levels of HDAC3

• Peptide competition:

  • Pre-incubate antibody with immunizing peptide

  • For HDAC3 clone 3G6, use peptide corresponding to amino acids 411-428 of human HDAC3

  • Should abolish or significantly reduce specific signal

• Multiple antibody validation:

  • Compare results using different antibody clones targeting distinct epitopes

  • Compare monoclonal (more specific) vs. polyclonal (higher sensitivity) antibodies

• Cross-reactivity assessment:

  • Test against recombinant HDAC family members (especially class I HDACs)

  • Western blot analysis to confirm single band at expected molecular weight (49 kDa)

• Application-specific controls:

  • For ChIP: IgG control, input control, positive and negative genomic regions

  • For IF/IHC: Secondary antibody only, isotype control

  • For IP: IgG control, input control

Published research has successfully used HDAC3 antibodies in knockout/knockdown validation studies, with eight publications specifically demonstrating such validations .

How can HDAC3 antibodies be used to investigate the role of HDAC3 in neuroinflammation and spinal cord injury?

HDAC3 antibodies play a crucial role in investigating neuroinflammation and spinal cord injury (SCI) recovery mechanisms:

• Monitoring HDAC3 expression after injury:

  • Immunohistochemistry of spinal cord sections at different time points post-injury

  • Co-staining with cell-type markers (microglia/macrophage markers CD11b, Iba1)

  • Quantitative analysis of HDAC3 expression levels

Research has shown that SCI results in upregulation of HDAC3 in innate immune cells at the injury site .

• Investigating HDAC3 in microglia/macrophage polarization:

  • Use HDAC3 antibodies in flow cytometry to assess HDAC3 levels in different microglial phenotypes

  • Combine with markers for pro-inflammatory (M1) vs. anti-inflammatory (M2) states

  • Correlate HDAC3 expression with inflammatory cytokine production

• Examining effects of HDAC3 inhibition:

  • Treat cells/animals with selective HDAC3 inhibitors

  • Use HDAC3 antibodies to confirm target engagement

  • Assess changes in inflammatory gene expression

  • Correlate with functional recovery outcomes

Studies have demonstrated that blocking HDAC3 with selective small molecule inhibitors shifts microglia/macrophage responses toward inflammatory suppression, resulting in neuroprotective phenotypes and improved functional recovery in SCI models .

• ChIP analysis of inflammatory gene regulation:

  • Use HDAC3 antibodies in ChIP to identify binding to inflammatory gene promoters

  • Compare binding patterns between resting, activated, and HDAC3 inhibitor-treated microglia

  • Link epigenetic changes to functional outcomes

Research has shown that HDAC3 activity is largely responsible for histone deacetylation and inflammatory responses of primary microglia to classic inflammatory stimuli .

What approaches can be used to study HDAC3's role in antitumor immunity using antibody-based techniques?

Based on emerging research on HDAC3's role in regulating antitumor immunity, several antibody-based approaches can be employed:

• Multi-parameter flow cytometry:

  • Use HDAC3 antibodies to assess expression in tumor and immune cells

  • Combine with markers for T cells (CD3, CD8), myeloid cells, and activation markers

  • Compare HDAC3 levels between responders and non-responders to immunotherapy

• Multiplex immunohistochemistry/immunofluorescence:

  • Co-stain tumor tissues for HDAC3, chemokines (CXCL9/10/11), and immune cell markers

  • Analyze spatial relationships between HDAC3-expressing cells and immune infiltrates

  • Quantify using digital pathology approaches

Research has demonstrated an inverse correlation between HDAC3 and CXCL10 expression in hepatocellular carcinoma tissues, which correlates with CD8+ T-cell infiltration and patient survival .

• Single-cell analysis:

  • Use HDAC3 antibodies in single-cell protein profiling

  • Correlate with single-cell transcriptomics to link HDAC3 expression with cell states

  • Identify specific cell populations where HDAC3 modulation affects immune function

• ChIP-Seq coupled with RNA-Seq:

  • Use HDAC3 antibodies in ChIP-Seq to map genomic binding sites

  • Compare binding patterns between tumor cells and immune cells

  • Integrate with RNA-Seq to identify HDAC3-regulated genes in each cell type

  • Focus on immune signaling pathways and chemokine expression

• In vivo models with genetic manipulation:

  • Generate conditional HDAC3 knockout in specific cell types

  • Use HDAC3 antibodies to confirm deletion

  • Assess tumor growth, immune infiltration, and response to immunotherapy

Research findings indicate that tumor-specific inactivation of HDAC3 suppresses tumor growth by activating antitumor immunity, specifically by enhancing CXCL9/10/11 expression and recruiting CXCR3+ T cells into the tumor microenvironment .

How can I use HDAC3 antibodies to investigate changes in HDAC3 localization and activity following drug treatment?

Investigating HDAC3 localization and activity changes following drug treatment requires multiple complementary approaches:

• Subcellular fractionation and Western blotting:

  • Separate nuclear, cytoplasmic, and chromatin-bound fractions

  • Use HDAC3 antibody (1:500-1:3000 dilution) to detect redistribution following treatment

  • Include markers for different cellular compartments (GAPDH for cytoplasm, Histone H3 for chromatin)

• Live-cell imaging with fluorescently tagged antibody fragments:

  • Use Fab fragments of HDAC3 antibodies conjugated to fluorophores

  • Track real-time changes in HDAC3 localization following drug addition

  • Combine with subcellular markers to confirm localization patterns

• Proximity ligation assay (PLA):

  • Use HDAC3 antibodies with antibodies against known interaction partners

  • Measure changes in protein-protein interactions following drug treatment

  • Quantify interaction events per cell in control vs. treated conditions

• Activity-based assays:

  • Immunoprecipitate HDAC3 using specific antibodies

  • Measure deacetylase activity of immunoprecipitated complexes

  • Compare activity levels before and after drug treatment

• ChIP-Seq before and after treatment:

  • Use HDAC3 antibodies in ChIP-Seq to map genomic binding sites

  • Compare binding patterns before and after drug treatment

  • Correlate with changes in histone acetylation patterns and gene expression

For HDAC3 inhibitor studies, research has demonstrated that selective inhibition alters HDAC3's genomic distribution and affects its ability to regulate key target genes such as chemokines CXCL9/10/11, which play important roles in immune cell recruitment and antitumor immunity .

How might HDAC3 antibodies contribute to research on HDAC3 as a therapeutic target in combined epigenetic-immunotherapy approaches?

HDAC3 antibodies can significantly advance research on combined epigenetic-immunotherapy approaches:

• Target engagement studies:

  • Use HDAC3 antibodies to confirm specific inhibition by HDAC3-selective compounds

  • Assess changes in HDAC3 binding to chromatin following inhibitor treatment

  • Correlate with immune-related gene expression changes

• Biomarker development:

  • Develop IHC protocols using HDAC3 antibodies for patient stratification

  • Correlate HDAC3 expression levels with response to HDAC3 inhibitors

  • Combine with immune markers to predict response to combination therapy

• Mechanism-of-action studies:

  • Use HDAC3 antibodies to investigate how HDAC3 inhibition enhances immunotherapy

  • Focus on chemokine expression (CXCL9/10/11) and T-cell recruitment

  • Examine changes in PD-L1 and other immune checkpoint molecules

Research has shown that BCL6/SMRT/HDAC3 complexes mediate aberrant transcriptional silencing of genes regulating B-cell signaling and immune response in CREBBP-mutated B-cell lymphoma, and selective inhibition of HDAC3 represents a novel mechanism-based immune epigenetic therapy for these lymphomas .

• Combination therapy development:

  • Test HDAC3 inhibitors with various immunotherapies

  • Use HDAC3 antibodies to track target modulation

  • Correlate changes in HDAC3 activity with immune activation markers

• Resistance mechanism studies:

  • Use HDAC3 antibodies to investigate changes in expression/activity in resistant tumors

  • Examine HDAC3 complex formation in sensitive vs. resistant samples

  • Identify compensatory mechanisms that overcome HDAC3 inhibition

What are the best approaches for multiplexed detection of HDAC3 alongside other epigenetic regulators?

For comprehensive epigenetic profiling involving HDAC3 and other regulators:

• Multiplex immunofluorescence (mIF):

  • Use HDAC3 antibody (1:50-1:500 dilution) in combination with antibodies to other epigenetic regulators

  • Employ spectral unmixing to resolve multiple fluorophores

  • Use sequential staining protocols to prevent cross-reactivity

  • Include markers for histone modifications (H3K9ac, H3K27ac)

• Mass cytometry (CyTOF):

  • Label HDAC3 antibodies with rare earth metals

  • Combine with antibodies against other epigenetic regulators

  • Analyze at single-cell resolution

  • Correlate HDAC3 expression with other proteins across cell populations

• Imaging mass cytometry:

  • Apply metal-labeled HDAC3 antibodies to tissue sections

  • Maintain spatial context while detecting multiple proteins

  • Create spatial maps of epigenetic regulator expression

• Sequential ChIP (ChIP-reChIP):

  • First ChIP with HDAC3 antibody

  • Second ChIP with antibodies against other epigenetic regulators

  • Identify genomic regions co-bound by multiple factors

  • Compare binding patterns across different cell types or treatment conditions

• Co-immunoprecipitation coupled with mass spectrometry:

  • Use HDAC3 antibodies for immunoprecipitation

  • Identify co-precipitating epigenetic regulators by mass spectrometry

  • Confirm interactions by reverse Co-IP

  • Map protein interaction networks centered on HDAC3

These approaches can reveal how HDAC3 cooperates with other epigenetic regulators to control gene expression in contexts such as tumor microenvironment regulation and inflammatory responses.

How can I design a comprehensive validation strategy for a new HDAC3 antibody in my laboratory?

A comprehensive HDAC3 antibody validation strategy should include:

• Basic characterization:

  • Western blot to confirm correct molecular weight (49 kDa)

  • Peptide competition assay using the immunizing peptide

  • Testing in multiple cell lines with known HDAC3 expression

• Genetic validation:

  • Testing in HDAC3 knockout/knockdown models

  • Complementary testing with multiple HDAC3 antibody clones

  • Overexpression studies to confirm signal increase

• Cross-reactivity assessment:

  • Testing against recombinant HDAC family proteins

  • Comparison with other validated HDAC3 antibodies

  • Immunoprecipitation followed by mass spectrometry

• Application-specific validation:

  • For WB: Optimize conditions (1:500-1:3000 dilution range)

  • For IHC: Test multiple fixation and antigen retrieval methods

  • For ChIP: Validate enrichment at known HDAC3 targets (CXCL9/10/11 promoters)

  • For IF: Confirm subcellular localization patterns

• Functional validation:

  • Use in HDAC3 inhibitor studies to confirm expected changes

  • Apply in biologically relevant models with known HDAC3 functions

  • Compare results with published findings on HDAC3 biology

This systematic approach ensures reliable antibody performance across applications and provides confidence in experimental results involving HDAC3 in various research contexts.

What future directions are emerging for HDAC3 antibody applications in translational research?

Emerging applications for HDAC3 antibodies in translational research include:

• Liquid biopsy development:

  • Detection of circulating HDAC3-containing complexes

  • Association with treatment response and disease progression

  • Combination with other epigenetic biomarkers

• Single-cell epigenomic profiling:

  • Integration of HDAC3 antibodies into single-cell technologies

  • Mapping HDAC3 distribution across diverse cell populations

  • Linking HDAC3 activity to cell state transitions

• Spatial epigenomics:

  • Application of HDAC3 antibodies in spatial profiling technologies

  • Mapping HDAC3 distribution across tissue microarchitecture

  • Correlating with disease progression and therapeutic response

• Therapeutic monitoring:

  • Development of companion diagnostics for HDAC3 inhibitors

  • Tracking HDAC3 target engagement in clinical samples

  • Predicting responders to HDAC3-targeted therapies

• Immunotherapy biomarker development:

  • Using HDAC3/CXCL10 expression ratios to predict immunotherapy response

  • Developing multiplex IHC panels including HDAC3 and immune markers

  • Correlating HDAC3 expression with immune infiltration patterns